EGFR and central nervous system cancer: Importantly in our study, EGFR mutation was absent in LGGs from the neocortex, and the mutation rate was significantly lower than that in mesocortex LGGs, suggesting EGFR amplification in the mesocortex gliomas may be a potential predictor for survival.